博济医药：公司未来会继续专注主营业务并以临床业务为主，不断提升核心竞争力

Core Viewpoint - The company, Boji Pharmaceutical, is experiencing a decline in net profit due to a decrease in overall gross margin influenced by intensified industry competition before the third quarter of 2025 [1] Group 1: Financial Performance - The company's net profit is expected to decline year-on-year due to a decrease in overall gross margin [1] - Management expense ratio and R&D expense ratio have both decreased before the third quarter of 2025 as a result of enhanced internal management and cost reduction efforts [1] Group 2: Strategic Focus - The company will continue to focus on its core business, primarily clinical operations, to enhance its core competitiveness [1] - The company aims to make every effort to improve operational performance [1]